SEMAGLUTIDE

Information current as at: 1 July 2026

PBAC meeting date: November 2026

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Wegovy®
Form and strength:: Solution for injection 0.25 mg in 0.5 mL single dose pre-filled pen

Solution for injection 0.5 mg in 0.5 mL single dose pre-filled pen

Solution for injection 1 mg in 0.5 mL single dose pre-filled pen

Solution for injection 1.7 mg in 0.75 mL single dose pre-filled pen

Solution for injection 2.4mg in 0.75mL single dose pre-filled pen
Submission sponsor:: NOVO NORDISK PHARMACEUTICALS PTY. LIMITED
Condition/indication: (therapeutic use): Established atherosclerotic cardiovascular disease (eASCVD) with obesity
Listing requested:: To consider the sponsor's revised proposal for listing semaglutide for the treatment of adult patients with eASCVD, defined as a documented history of prior myocardial infarction or stroke, or symptomatic peripheral arterial disease, with a body mass index (BMI) greater than or equal to 35 kg/m2. This item was previously recommended by the PBAC at its November 2025 meeting.
Funding program:: PBS General Schedule
Request authority level:: Authority Required (Telephone/Online)
PBAC Submission type:: New PBS listing (–)
Comment:: --
Other PBAC consideration:: SEMAGLUTIDE

Submission received for:: November 2026 PBAC meeting
2Opportunity for consumer comment:: Open 22/07/2026 and close 16/09/2026 (see PBS Website)
3PBAC meeting:: Has not yet occurred
4PBAC outcome published:: Pending PBAC outcome (see PBAC Outcomes)
5Lodgement of required documentation:
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Case ID

a1305

Page last updated

23 July 2026

v.9.19